Silexion Therapeutics (SLXN) furnishes updated corporate presentation for conference

Rhea-AI Filing Summary

Silexion Therapeutics Corp furnished an updated corporate presentation that it plans to present on September 10, 2025 at the H.C. Wainwright Global Investment Conference in New York. The presentation was posted on the company’s website on September 2, 2025 and attached as Exhibit 99.1.

The company clarifies that this information is provided under a disclosure item that treats the material as “furnished” rather than “filed”, meaning it is not subject to certain liability provisions and will only be incorporated into other securities documents if specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162025-09-022025-09-020002022416slxn:OrdinarySharesParValue00135PerShareMember2025-09-022025-09-020002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-09-022025-09-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 2, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 2, 2025, Silexion Therapeutics Corp (the “Company”) posted to its website (https://silexion.com/) an updated corporate presentation that it will be presenting on September 10, 2025 at the H.C. Wainwright Global Investment Conference taking place from September 8-10, 2025, in New York. A copy of the presentation is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1	Corporate Presentation
104	Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: September 2, 2025	By: /s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics Corp (SLXN) announce in this 8-K filing?

Silexion Therapeutics Corp furnished an updated corporate presentation. The presentation was posted to its website on September 2, 2025 and will be used at the H.C. Wainwright Global Investment Conference. It is attached to the filing as Exhibit 99.1 for reference.

When and where will Silexion Therapeutics (SLXN) present its corporate deck?

The company will present its corporate deck on September 10, 2025. This presentation will occur at the H.C. Wainwright Global Investment Conference, which takes place from September 8–10, 2025, in New York, using the updated materials posted on its website.

How is the Silexion (SLXN) corporate presentation treated under securities laws?

The corporate presentation is treated as “furnished,” not “filed.” Information furnished under Item 7.01 is not subject to Section 18 liability and will only be incorporated into other Securities Act or Exchange Act documents if specifically referenced.

Where can investors access Silexion Therapeutics’ updated corporate presentation?

The updated corporate presentation is available on the company’s website. Silexion posted it at https://silexion.com/ on September 2, 2025, and also attached it as Exhibit 99.1 to the current report for ease of access.

What exhibits were included with Silexion Therapeutics’ September 2, 2025 8-K?

The filing includes two exhibits: 99.1 and 104. Exhibit 99.1 is the updated corporate presentation, and Exhibit 104 is the cover page interactive data file formatted in Inline XBRL, accompanying the current report.

Who signed the Silexion Therapeutics Corp (SLXN) 8-K report?

The 8-K was signed by Chief Executive Officer Ilan Hadar. The signature block shows that Silexion Therapeutics Corp caused the report to be signed on its behalf by Ilan Hadar as CEO, dated September 2, 2025.